Analysis

PremiumFeatures

Osaka has the science. Now it needs the business

Osaka has the science. Now it needs to build the companies, capital and global reach to turn that science into…

Catherine Longworth

Comment

A practical framework for choosing e-signatures in global trials

Projects

ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2-positive advanced gastric cancer

Projects

ZENBEXUS (iberdomide) for the Treatment of Multiple Myeloma, US

Comment

Sustaining long-term follow-up in cell and gene therapies

PremiumFeatures

ICH GCP Annex 2 will strengthen sponsor confidence in the use of DCTs and RWD

Features

Podcast: Bringing diversity to Alzheimer’s trials

Projects

XOLREMDI (mavorixafor) for the Treatment of WHIM Syndrome, US

Analysis

How real-world evidence can directly support innovation

Analysis

PPD affects races similarly, inequities lie in mental healthcare

GlobalData Healthcare

Analysis

Psychedelic treatments for mental health: Is there substance behind the hype?

News

Can Elon Musk’s Neuralink be trusted to put chips in your brain?

News

IRA lawsuits will be vital test of US’ ability to regulate pharma market

Analysis

How sovereign wealth funds are affecting industries and macroeconomics

Analysis

How sovereign wealth funds are affecting industries and macroeconomics

Analysis

Why does Kuwait struggle to attract FDI?

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close